219 related articles for article (PubMed ID: 25127861)
1. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
[TBL] [Abstract][Full Text] [Related]
2. NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner.
Neerincx A; Rodriguez GM; Steimle V; Kufer TA
J Immunol; 2012 May; 188(10):4940-50. PubMed ID: 22490867
[TBL] [Abstract][Full Text] [Related]
3. NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.
Ludigs K; Seguín-Estévez Q; Lemeille S; Ferrero I; Rota G; Chelbi S; Mattmann C; MacDonald HR; Reith W; Guarda G
PLoS Genet; 2015 Mar; 11(3):e1005088. PubMed ID: 25811463
[TBL] [Abstract][Full Text] [Related]
4. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
5. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
6. NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.
Staehli F; Ludigs K; Heinz LX; Seguín-Estévez Q; Ferrero I; Braun M; Schroder K; Rebsamen M; Tardivel A; Mattmann C; MacDonald HR; Romero P; Reith W; Guarda G; Tschopp J
J Immunol; 2012 Apr; 188(8):3820-8. PubMed ID: 22412192
[TBL] [Abstract][Full Text] [Related]
7. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells.
Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C
J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519
[TBL] [Abstract][Full Text] [Related]
8. Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins.
Robbins GR; Truax AD; Davis BK; Zhang L; Brickey WJ; Ting JP
J Biol Chem; 2012 Jul; 287(29):24294-303. PubMed ID: 22645137
[TBL] [Abstract][Full Text] [Related]
9. Emerging Major Histocompatibility Complex Class I-Related Functions of NLRC5.
Chelbi ST; Dang AT; Guarda G
Adv Immunol; 2017; 133():89-119. PubMed ID: 28215281
[TBL] [Abstract][Full Text] [Related]
10. NLRC5: a newly discovered MHC class I transactivator (CITA).
Meissner TB; Li A; Kobayashi KS
Microbes Infect; 2012 Jun; 14(6):477-84. PubMed ID: 22209772
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional coactivator, CIITA, is an acetyltransferase that bypasses a promoter requirement for TAF(II)250.
Raval A; Howcroft TK; Weissman JD; Kirshner S; Zhu XS; Yokoyama K; Ting J; Singer DS
Mol Cell; 2001 Jan; 7(1):105-15. PubMed ID: 11172716
[TBL] [Abstract][Full Text] [Related]
12. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
[TBL] [Abstract][Full Text] [Related]
13. CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression.
Downs I; Vijayan S; Sidiq T; Kobayashi KS
Biofactors; 2016 Jul; 42(4):349-57. PubMed ID: 27087581
[TBL] [Abstract][Full Text] [Related]
14. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.
Meissner TB; Li A; Biswas A; Lee KH; Liu YJ; Bayir E; Iliopoulos D; van den Elsen PJ; Kobayashi KS
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13794-9. PubMed ID: 20639463
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
16. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.
Kasuga Y; Ouda R; Watanabe M; Sun X; Kimura M; Hatakeyama S; Kobayashi KS
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2218955120. PubMed ID: 37279268
[TBL] [Abstract][Full Text] [Related]
17. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
18. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.
Wang Y; Xu M; Che M; Von Hofe E; Abbas A; Kallinteris NL; Lu X; Liss ZJ; Forman JD; Hillman GG
Hum Gene Ther; 2005 Feb; 16(2):187-99. PubMed ID: 15761259
[TBL] [Abstract][Full Text] [Related]
19. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
20. The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.
Meissner TB; Li A; Liu YJ; Gagnon E; Kobayashi KS
Biochem Biophys Res Commun; 2012 Feb; 418(4):786-91. PubMed ID: 22310711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]